3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024_老虎社区_美港股上老虎

3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024

Motley Fool2021-09-10

These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years. Key Points Sales growth alone doesn't often tell the full story behind a company's ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

dahae
·2021-09-11
👛
回复
1
举报
收起
- dahae:
  👛
  2021-09-11
  回复
  举报
老木不朽
·2021-09-11
L
回复
1
举报
Tanyl
·2021-09-10
Planning to take option in MRNA & NIO
回复
3
举报
收起
- jaswsf:
  Act fast
  2021-09-11
  回复
  举报
- Starbucks:
  Waiting to biy the dips!
  2021-09-11
  回复
  举报
chaisiewling
·2021-09-10
Like
回复
3
举报
收起
- chaisiewling:
  Like
  2021-09-10
  回复
  举报
KBchan
·2021-09-10
Like
回复
2
举报
Calvinq
·2021-09-10
Like comment pls. NIO 🚀
回复
5
举报
glorify
·2021-09-10
Wow! Great!👍
回复
5
举报
BBBBBBBBBB
·2021-09-10
Ok
回复
2
举报
Spaclover
·2021-09-10
T
回复
4
举报
收起
- Spaclover:
  T
  2021-09-10
  回复
  举报
peanutz
·2021-09-10
Hows NIO
回复
3
举报
PanaCota
·2021-09-10
Hi
回复
2
举报
收起
- Autoph:
  Hi
  2021-09-10
  回复
  举报
- Esther1121:
  Hi
  2021-09-10
  回复
  举报
breAkdaWn
·2021-09-10
Nio made in China!
回复
3
举报
Success9999
·2021-09-10
Talking about Mordena, it is suddenly become household name already.
回复
1
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2166327584?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-10 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2166327584","market":"us","top_or_hot":-1,"title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","media":"Motley Fool","content":"<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNOW","symbol_name":"Snowflake","start_time":0,"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","article_id":"2166327584","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","pubTimestamp":1631277360,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNOW":"Snowflake","NIO":"蔚来","MRNA":"Moderna, Inc."},"translate_title":"3超热门成长股预计到2024年销售增长559%至809%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"NIO":0.9,"SNOW":0.9},"content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":881405360,"gmtCreate":1631373558750,"gmtModify":1631888558016,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"htmlText":"👛","listText":"👛","text":"👛","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/881405360","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5833455,"gmtCreate":1631373564485,"gmtModify":1631888558016,"authorId":3560092322694803,"author":{"id":3560092322694803,"idStr":"3560092322694803","authorId":3560092322694803,"name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":881405360,"type":1,"supId":0,"prevId":0,"content":"👛","text":"👛","html":"👛"}],"langContent":"EN"},{"id":881344527,"gmtCreate":1631310192169,"gmtModify":1631888946572,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"htmlText":"L","listText":"L","text":"L","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881344527","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":881902811,"gmtCreate":1631283717033,"gmtModify":1631892929596,"author":{"id":"4087109808120260","authorId":"4087109808120260","name":"Tanyl","avatar":"https://static.tigerbbs.com/174329973340cf0f5b68791ee5b08afd","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"4087109808120260","authorIdStr":"4087109808120260"},"htmlText":"Planning to take option in MRNA &amp; NIO","listText":"Planning to take option in MRNA &amp; NIO","text":"Planning to take option in MRNA & NIO","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/881902811","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5830792,"gmtCreate":1631350286530,"gmtModify":1631892929642,"authorId":3571893886885807,"author":{"id":3571893886885807,"idStr":"3571893886885807","authorId":3571893886885807,"name":"jaswsf","avatar":"https://static.tigerbbs.com/ed600b3aaba5cb409e893412ae0ee2a9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":881902811,"type":1,"supId":0,"prevId":0,"content":"Act <u>fast</u>","text":"Act <u>fast</u>","html":"Act <u>fast</u>"},{"id":5823388,"gmtCreate":1631298643011,"gmtModify":1631892929599,"authorId":3573818563583937,"author":{"id":3573818563583937,"idStr":"3573818563583937","authorId":3573818563583937,"name":"Starbucks","avatar":"https://static.tigerbbs.com/adf9c30b19f3cc477ca4f1198d2c8b81","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":881902811,"type":1,"supId":0,"prevId":0,"content":"Waiting to biy the dips! ","text":"Waiting to biy the dips! ","html":"Waiting to biy the dips! "}],"langContent":"EN"},{"id":881054366,"gmtCreate":1631282755555,"gmtModify":1631887967324,"author":{"id":"3584578813080112","authorId":"3584578813080112","name":"chaisiewling","avatar":"https://static.tigerbbs.com/a9a4a1e448f0d39c51c24533166eb658","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584578813080112","authorIdStr":"3584578813080112"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/881054366","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5820909,"gmtCreate":1631282763942,"gmtModify":1631887967332,"authorId":3584578813080112,"author":{"id":3584578813080112,"idStr":"3584578813080112","authorId":3584578813080112,"name":"chaisiewling","avatar":"https://static.tigerbbs.com/a9a4a1e448f0d39c51c24533166eb658","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":881054366,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"EN"},{"id":881056426,"gmtCreate":1631282651665,"gmtModify":1631891319489,"author":{"id":"3582453112692311","authorId":"3582453112692311","name":"KBchan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582453112692311","authorIdStr":"3582453112692311"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881056426","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":881011505,"gmtCreate":1631281092507,"gmtModify":1631891273149,"author":{"id":"3581665869451416","authorId":"3581665869451416","name":"Calvinq","avatar":"https://static.tigerbbs.com/3c005973d00b3597177b005554456e28","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581665869451416","authorIdStr":"3581665869451416"},"htmlText":"Like comment pls. NIO 🚀","listText":"Like comment pls. NIO 🚀","text":"Like comment pls. NIO 🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881011505","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":881035886,"gmtCreate":1631280901345,"gmtModify":1631889747579,"author":{"id":"4087698744325360","authorId":"4087698744325360","name":"glorify","avatar":"https://static.tigerbbs.com/bb1a0d88b0029e6cb51d7065d6b143e5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087698744325360","authorIdStr":"4087698744325360"},"htmlText":"Wow! Great!👍","listText":"Wow! Great!👍","text":"Wow! Great!👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881035886","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":881091180,"gmtCreate":1631279916840,"gmtModify":1631891882425,"author":{"id":"3581562365927542","authorId":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581562365927542","authorIdStr":"3581562365927542"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881091180","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":881093328,"gmtCreate":1631279814064,"gmtModify":1631889303870,"author":{"id":"3565238397133271","authorId":"3565238397133271","name":"Spaclover","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3565238397133271","authorIdStr":"3565238397133271"},"htmlText":"T","listText":"T","text":"T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/881093328","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5820177,"gmtCreate":1631279822770,"gmtModify":1631889303868,"authorId":3565238397133271,"author":{"id":3565238397133271,"idStr":"3565238397133271","authorId":3565238397133271,"name":"Spaclover","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":881093328,"type":1,"supId":0,"prevId":0,"content":"T","text":"T","html":"T"}],"langContent":"EN"},{"id":881006292,"gmtCreate":1631278934516,"gmtModify":1631892868424,"author":{"id":"4092751843658000","authorId":"4092751843658000","name":"peanutz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4092751843658000","authorIdStr":"4092751843658000"},"htmlText":"Hows NIO","listText":"Hows NIO","text":"Hows NIO","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881006292","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883774189,"gmtCreate":1631278252141,"gmtModify":1632883477531,"author":{"id":"3581588474178431","authorId":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581588474178431","authorIdStr":"3581588474178431"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/883774189","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5820101,"gmtCreate":1631279349571,"gmtModify":1631894633379,"authorId":3575069195817790,"author":{"id":3575069195817790,"idStr":"3575069195817790","authorId":3575069195817790,"name":"Autoph","avatar":"https://static.tigerbbs.com/b0922dd4320d261e4f2f56fc4a467c2a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883774189,"type":1,"supId":0,"prevId":0,"content":"Hi","text":"Hi","html":"Hi"},{"id":5820096,"gmtCreate":1631279316686,"gmtModify":1631894633370,"authorId":4088562122230350,"author":{"id":4088562122230350,"idStr":"4088562122230350","authorId":4088562122230350,"name":"Esther1121","avatar":"https://static.tigerbbs.com/b3c5d27cbf70f469e226be06fce2a237","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883774189,"type":1,"supId":0,"prevId":0,"content":"Hi","text":"Hi","html":"Hi"}],"langContent":"EN"},{"id":883772950,"gmtCreate":1631277944570,"gmtModify":1631277944570,"author":{"id":"3569809505691000","authorId":"3569809505691000","name":"breAkdaWn","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3569809505691000","authorIdStr":"3569809505691000"},"htmlText":"Nio made in China!","listText":"Nio made in China!","text":"Nio made in China!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883772950","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883772092,"gmtCreate":1631277914416,"gmtModify":1631893053671,"author":{"id":"3581933145667506","authorId":"3581933145667506","name":"Success9999","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581933145667506","authorIdStr":"3581933145667506"},"htmlText":"Talking about Mordena, it is suddenly become household name already.","listText":"Talking about Mordena, it is suddenly become household name already.","text":"Talking about Mordena, it is suddenly become household name already.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883772092","repostId":2166327584,"repostType":4,"repost":{"id":"2166327584","pubTimestamp":1631277360,"share":"https://www.laohu8.com/m/news/2166327584?lang=&edition=full","pubTime":"2021-09-10 20:36","market":"us","language":"en","title":"3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2166327584","media":"Motley Fool","summary":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.","content":"<blockquote>\n <b>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Sales growth alone doesn't often tell the full story behind a company's outlook.</li>\n</ul>\n<p>Things couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.</p>\n<p>Over the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/ee55796575e48ba3143c099af095e386\" tg-width=\"700\" tg-height=\"535\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: 809% implied sales growth by 2024</h3>\n<p>Perhaps it comes as little shock that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, <b>Moderna</b> (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.</p>\n<p>As you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by <b>Pfizer</b>/<b>BioNTech</b>&nbsp;for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.</p>\n<p>While there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.</p>\n<p>So, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.</p>\n<p>Maybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h3>Nio: 562% implied sales growth by 2024</h3>\n<p>Speaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.</p>\n<p>Nio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.</p>\n<p>Nio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.</p>\n<p>What's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.</p>\n<p>Nio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.</p>\n<p><img src=\"https://static.tigerbbs.com/6055c9ae2e82ded9736a78b024919efc\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p>\n<h3><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: 559% implied sales growth by 2024</h3>\n<p>Another ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.</p>\n<p>Prior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.</p>\n<p>What makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.</p>\n<p>Snowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.</p>\n<p>In June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.</p>\n<p>The bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/3-growth-stocks-increase-sales-559-to-809-by-2024/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166327584","content_text":"These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.\n\nKey Points\n\nSales growth alone doesn't often tell the full story behind a company's outlook.\n\nThings couldn't be any better for growth stocks. Historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and a free-spending Congress have rolled out the red carpet for fast-growing companies. Access to cheap capital is abundant, and growth stocks have deployed their cash to hire, innovate, and even acquire other businesses.\nOver the next couple of years, a handful of ultra-popular growth stocks are really expected to put the pedal to the metal. The following three growth stocks are projected by Wall Street to deliver aggregate sales increases ranging from 559% to 809% by 2024.\n\nImage source: Getty Images.\nModerna: 809% implied sales growth by 2024\nPerhaps it comes as little shock that one of the most successful coronavirus disease 2019 (COVID-19) vaccine developers, Moderna (NASDAQ:MRNA), is expected to be one of the fastest-growing companies on the planet over the next four years. After reporting $803 million in 2020 sales, Wall Street's consensus currently has it pegged for $7.3 billion in revenue by 2024. Interestingly, this is down significantly from the $20 billion in net product sales Moderna is forecasting for 2021.\nAs you're probably aware, there are around a half-dozen global COVID-19 vaccines, but few have offered the initial efficacy that mRNA-1273 brings to the table. Moderna's November-released trial data showed a vaccine efficacy (VE) of 94.1%, which is only rivaled by the 95% initial VE reported by Pfizer/BioNTech for their vaccine. Moderna has become one of the two core vaccination options in developed markets. The company anticipates producing between 800 million and 1 billion doses this year, and following up with between 2 billion and 3 billion doses in 2022.\nWhile there is no shortage of question marks surrounding COVID-19, the biggest looming uncertainty for vaccine developers is whether booster shots or recurring annual vaccines will become necessary. Though we still don't know the answer to that question, the data has begun to point to the need for a third booster shot for vaccinated individuals. In other words, Moderna could be looking at its one-time bump in sales becoming something of a recurring revenue stream.\nSo, why the drop-off from $20 billion in net product sales in 2021 to Wall Street's estimate of $7.3 billion by 2024? One reason is likely to be competition. We'll almost certainly see a handful of new vaccines enter the market in the coming year(s), which'll reduce Moderna's potential patient pool. There's also the aforementioned uncertainty as to whether or not COVID-19 vaccines will be ongoing for years to come, or if a three-shot course will prove effective.\nMaybe the biggest concern of all is that mRNA-1273 is the company's only revenue-generation product. With a $168 billion market cap, things would have to be perfect from here on out for Moderna to justify this valuation -- and that's unlikely.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: 562% implied sales growth by 2024\nSpeaking of pedal-to-the-metal growth, electric vehicle (EV) manufacturer Nio (NYSE:NIO) is projected to lay down some serious rubber from a sales perspective. After reporting $2.55 billion in sales last year, Wall Street is counting on Nio to reach nearly $16.9 billion in full-year revenue by 2024.\nNio finds itself in the right place at the right time in multiple respects. The battle against climate change is driving businesses and consumers to act. One of the more logical shifts we're witnessing is a push toward the electrification of consumer vehicles and enterprise fleets. This'll be a multi-decade replacement cycle, providing ample opportunity for multiple EV makers to shine. And Nio is headquartered in China, which happens to be the largest auto market in the world. As I said, right place and right time.\nNio would love nothing more than to expand its production capacity at the moment, but supply chain issues concerning the chips used in new automobile production are hurting capacity throughout the entire industry. Nio delivered 5,880 vehicles in August, but had delivered around 8,000 vehicles in each of the previous two months. Once these supply issues ease, Nio should push for an annual delivery run-rate of 150,000 EVs.\nWhat's equally exciting is the innovation we're seeing on all fronts from Nio. In addition to introducing a new vehicle each year, management rolled out a battery-as-a-service subscription program last year. This program will reduce the upfront cost of Nio's EVs in exchange for enrolling buyers into a fee-based monthly program that'll allow them to swap out or upgrade their batteries in the future. Effectively, Nio is exchanging some near-term sales for steadier long-term cash flow, higher margins, and improved customer loyalty.\nNio isn't cheap by any means, but Wall Street's lofty sales projections are achievable.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 559% implied sales growth by 2024\nAnother ultra-popular growth stock that's expected to move the revenue needle in a big way through 2024 is cloud data-warehousing company Snowflake (NYSE:SNOW). Taking into account that Snowflake's fiscal year doesn't coincide with a normal calendar year, we're looking at revenue growing from $592 million in fiscal 2021 to about $3.9 billion in fiscal 2025. That's a projected increase of 559%.\nPrior to the pandemic, we were witnessing a pretty steady shift by businesses to create an online presence and move data into the cloud. But with the pandemic ongoing, this shift sped up considerably. With hybrid workplaces now a common theme and more data than ever stored in the cloud, demand for cloud infrastructure services couldn't be more robust.\nWhat makes Snowflake so intriguing is the company's unique operating approach. For instance, its infrastructure is built atop many of the most popular cloud services, such as S3, Azure, and Google Cloud. Normally, sharing data between these competing services isn't easy. However, it's a piece of cake for Snowflake members since its infrastructure is layered on top of these services.\nSnowflake is also different in the way it charges its clients. Instead of pushing its customers toward a subscription-based service, Snowflake charges customers based on the amount of data stored and Snowflake Compute Credits used. In doing so, it's created a more transparent pricing model that's clearly resonating with its customers. After all, existing clients spent 69% more in the most recent quarter than they did in the prior-year period.\nIn June, the company's management team outlined their goal of reaching $10 billion in annual product sales by fiscal 2029. It's a lofty target, but one that's achievable considering how much data is being shifted into the cloud.\nThe bigger question that remains unanswered is whether Snowflake can offer meaningful upside at a whopping multiple of 50 times Wall Street's fiscal 2023 sales forecast. My inclination is to say no, but we also haven't seen another company offer the data-warehousing scale that Snowflake can deliver.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":88,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}